Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Medium Dose of Cytarabine and Mitoxantrone

Conditions: Chemotherapy
Acute Myelogenous Leukemia

Interventions: Device: Flow Cytometer
Drug: Mitoxantrone
Drug: Cytarabine

First Posted Date: 2019-07-18

Last Posted Date: 2019-07-18

Lead Sponsor: Shenzhen People's Hospital

Target Recruit Count: 250

Registration Number: NCT04024241

Locations: 🇨🇳
Shenzhen, Shenzhen, Guangdong, China

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Drug: Cytarabine
Procedure: Echocardiogram Recording
Drug: Etoposide Phosphate
Drug: Mitoxantrone Hydrochloride
Procedure: Multigated Acquisition Scan
Drug: Peposertib

First Posted Date: 2019-06-12

Last Posted Date: 2024-10-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT03983824

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 12 locations

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Phase 2

Active, not recruiting

Conditions: Central Nervous System Lymphoma
Secondary Central Nervous System Lymphoma

Interventions: Drug: TEDD-R
Drug: TEDDI-R
Drug: Ibrutinib
Drug: Cytarabine
Drug: Isavuconazole
Drug: Methotrexate

First Posted Date: 2019-05-28

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT03964090

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

Phase 1

Active, not recruiting

Conditions: B-cell Acute Lymphoblastic Leukemia

Interventions: Drug: Inotuzumab ozogamicin
Drug: Prednisone Pill
Drug: Daunorubicin
Drug: Vincristine
Drug: Cytarabine
Drug: Methotrexate
Drug: Pegaspargase

First Posted Date: 2019-05-24

Last Posted Date: 2023-08-22

Lead Sponsor: University of Virginia

Target Recruit Count: 36

Registration Number: NCT03962465

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 1 locations

Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes
Transplant-Related Hematologic Malignancy

Interventions: Drug: Fludarabine
Drug: ARA-C
Drug: Treosulfan
Procedure: Peripheral Blood Stem Cell Transplant

First Posted Date: 2019-05-23

Last Posted Date: 2023-11-18

Lead Sponsor: Ciceri Fabio

Target Recruit Count: 15

Registration Number: NCT03961919

Locations: 🇮🇹
Ospedale San Raffaele, Milano, Lombardia, Italy

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Phase 3

Recruiting

Conditions: Testicular Leukemia
B Lymphoblastic Lymphoma
B Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
Central Nervous System Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Calaspargase Pegol
Procedure: Bone Scan
Drug: Cyclophosphamide
Procedure: Computed Tomography
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Drug: Cytarabine
Drug: Doxorubicin Hydrochloride
Drug: Leucovorin Calcium
Biological: Inotuzumab Ozogamicin
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Procedure: Magnetic Resonance Imaging
Drug: Prednisolone
Other: Questionnaire Administration
Radiation: Radiation Therapy
Procedure: Positron Emission Tomography
Drug: Thioguanine
Drug: Vincristine Sulfate

First Posted Date: 2019-05-22

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 4997

Registration Number: NCT03959085

Locations: 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Michigan State University Clinical Center, East Lansing, Michigan, United States
🇺🇸
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States

and more 225 locations

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Phase 3

Recruiting

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: DFP-10917
Drug: Cytarabine
Drug: Azacitidine
Drug: Decitabine
Drug: Mitoxantrone
Drug: Etoposide
Drug: Fludarabine
Drug: Idarubicin
Drug: Venetoclax
Drug: Cladribine

First Posted Date: 2019-04-24

Last Posted Date: 2022-10-20

Lead Sponsor: Delta-Fly Pharma, Inc.

Target Recruit Count: 450

Registration Number: NCT03926624

Locations: 🇺🇸
University of California, Irvine, California, United States
🇺🇸
Decatur Memorial Hospital-Cancer Care Specialists of Central IL, Decatur, Illinois, United States
🇺🇸
The University of Mississippi Medical Center, Jackson, Mississippi, United States

and more 36 locations

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

Phase 3

Active, not recruiting

Conditions: B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma
Down Syndrome

Interventions: Drug: Asparaginase Erwinia chrysanthemi
Drug: Cyclophosphamide
Biological: Blinatumomab
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Mercaptopurine Oral Suspension
Drug: Methotrexate
Drug: Pegaspargase
Radiation: Radiation Therapy
Drug: Prednisone
Drug: Prednisolone
Drug: Thioguanine
Drug: Vincristine Sulfate

First Posted Date: 2019-04-16

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6720

Registration Number: NCT03914625

Locations: 🇨🇦
IWK Health Centre, Halifax, Nova Scotia, Canada
🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

and more 225 locations

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Inotuzumab ozogamicin
Drug: Methotrexate
Drug: Hydrocortisone
Drug: Cytarabine
Drug: Diphenhydramine
Drug: Acetaminophen
Drug: Methylprednisolone

First Posted Date: 2019-04-12

Last Posted Date: 2024-08-19

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 32

Registration Number: NCT03913559

Locations: 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Gemtuzumab Ozogamicin
Drug: Midostaurin

First Posted Date: 2019-04-03

Last Posted Date: 2024-12-20

Lead Sponsor: Uma Borate

Target Recruit Count: 18

Registration Number: NCT03900949

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy